HRS-4029

Phase 2Small molecule

BBeijing Suncadia Pharmaceuticals Co., Ltd

HRS-4029 is one of 19 small molecule programs targeting Acute Ischemic Stroke. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Acute Ischemic StrokeNot yet recruiting

Single Ascending DoseNot yet recruiting

Acute Ischemic StrokePhase 2

Not yet recruiting

Single Ascending DosePhase 1

Not yet recruiting

Competition

Competitive Landscape

16 competitors in Single Ascending Dose

#DrugCompanyPhaseTrials

HRS-4029

BBeijing Suncadia Pharmaceuticals Co., Ltd

Phase 2

1 2

WVE-006

WWave Life Sciences Ltd.

Phase 2

1 3

SYH2085

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Phase 1

1 4

JMT202

SShanghai JMT-Bio Inc.

Phase 1

1 5

Gensci142

Changchun GeneScience Pharmaceutical Co., Ltd.

Phase 1

1 6

DT-216P2

DDesign Therapeutics, Inc.

Phase 1

1 7

NM-101

NNeuramedy Co. Ltd.

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 2Not yet recruiting

Acute Ischemic Stroke

NCT07739160

Clinical

Trials by Indication[1]

Single Ascending Dose1 trial

A Single Ascending Dose of HRS-4029 in Healthy Subjects

Not yet recruiting·BBeijing Suncadia Pharmaceuticals Co., Ltd·Phase 1·NCT06905314·55 enrolled

Acute Ischemic Stroke1 trial

The Efficacy and Safety of HRS-4029 for the Treatment of Acute Ischemic Stroke: a Multicenter, Randomized, Double-blind, Placebo-controlled, Phase II Clinical Trial

Not yet recruiting·BBeijing Suncadia Pharmaceuticals Co., Ltd·Phase 2·NCT07739160·340 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for HRS-4029. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — HRS-4029 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for HRS-4029. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Beijing Suncadia Pharmaceuticals Co., Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: BBeijing Suncadia Pharmaceuticals Co., Ltd

HRS-4029

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Single Ascending Dose1 trial

Acute Ischemic Stroke1 trial

References

Drug Info

Quick Facts

Related News